MapLight Therapeutics, Inc. (MPLT)
13.06
-0.25
(-1.88%)
USD |
NASDAQ |
Sep 02, 16:00
13.05
-0.01
(-0.08%)
Pre-Market: 20:00
MapLight Therapeutics Research and Development Expense (TTM) : 198.70M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 198.70M |
| March 31, 2026 | 171.98M |
| December 31, 2025 | 138.08M |
| Date | Value |
|---|---|
| September 30, 2025 | 88.92M |
| June 30, 2025 | 77.17M |
| March 31, 2025 | 60.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Evommune, Inc. | 83.77M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Cullinan Therapeutics, Inc. | 171.47M |
| Mineralys Therapeutics, Inc. | 301.59M |
| Apogee Therapeutics, Inc. | 240.59M |